Abstract: A simple and sensitive stability indicating HPLC method is developed for the quantification of rivaroxaban in bulk and tablet dosage form. Chromatographic separation was achieved on an ACE-Ciano column (250 mm x 4.6 mm, 5 μm particle size). The mobile phase consists of 0.1M sodium acetate and methanol (60:40 v/v) and was delivered at a flow rate of 1 mL/min. A UV detector was used for the detection. The rivaroxaban was subjected to stress conditions for the assessment of the stability-indicating nature of the method. The method was validated as per ICH guidelines. The linearity is obtained in the range of 1-120 μg/mL. The limit of detection and quantification values is 0.194 μg/mL and 0.648 μg/mL respectively. The intra and inter-day %RSD values were below 1%. Intra and inter-day accuracies were within 100.10% and 100.40%, respectively. Degradation products resulting from the stress studies have no interfere with the detection of rivaroxaban. The average recovery of rivaroxaban in tablet dosage form was 99.74% with %RSD of 0.421%. The developed method was proved adequate for quantitative determination of rivaroxiban in presence of its degradation products.
Introduction

Rivaroxaban
(RXN), (S)-5-Chlor-N-{2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-lmethyl}thiophen-2-carbamid, is a novel, oral, direct Factor Xa inhibitor approved for the prevention of venous thromboembolism in adult patients who have undergone hip or knee replacement surgery 1, 2 .
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Chem Sci Trans., 2014, 3(4), [1546] [1547] [1548] [1549] [1550] [1551] [1552] [1553] [1554] Muralikrishna and Kasad 3 , Sekaran et al. 4 Satyanarayana and Madhavi 5 have determined RXN in formulations using spectrophotometry. Satyanarayana and Madhavi 6 and Sekhar et al. 7 have reported RP-HPLC method for the determination of RXN in formulations. Assay of RXN in human plasma by HPLC-MS/MS has been reported by Rohde 8 . Anti-factor Xa chromogenic assay method have been applied for quantification of RXN in human plasma by Mani et al. 9 Asmis et al. 10 Samama et al. 11 and Harenberg et al. 12 Stability indicating HPLC method is the most preferential technique for the analysis of drugs in the presence of its degradants. Celebier et al. 13 and Kasad and Muralikrishna 14 described stability indicating HPLC methods for the quantification of RXN.
The present manuscript describes a sensitive, selective, precise and accurate stability indicating HPLC method for the quantification of RXN in tablet formulations in accordance with ICH guidelines 15, 16 .
Experimental
The chromatographic analysis was performed with Waters Alliance HPLC system equipped with 2695 separation modules having 2996 photodiode array detector. HPLC analysis was conducted in an ACE-Ciano column (250 mm x 4.6 mm, 5 μm particle size).
Chemicals
Solvents and chemicals used were of HPLC and analytical grade, respectively. Pharmaceutical grade RXN was kindly supplied by Rainbow Pharma Training Lab, Hyderabad. Xeralto tablets (Bayer India Limited Mumbai, India) claimed to contain 10 mg of RXN were purchased from the local pharmacy store.
Mobile phase preparation
The mobile phase is composed of 0.1M sodium acetate (Merck, Mumbai, India) and methanol (Thermo Fisher Scientific India Pvt. Ltd, Mumbai, India) in the ratio of 60:40 (v/v). The pH of the mobile phase was adjusted to 5.5 with 85% orthophosphoric acid (Thermo Fisher Scientific India Pvt. Ltd, Mumbai, India). The mobile phase was degassed and filtered via 0.45 μm membrane filter before use.
Stock Standard solution preparation
A stock standard solution of RXN (1 mg/mL) was prepared in the mobile phase.
Chromatographic conditions
The HPLC parameters such as run time 6 minutes, 1 mL/min as flow rate, injection volume of 10 μL and column temperature of 30 °C were finalized during development. RXN was detected at 247nm.
General assay procedure
The stock standard solution (1 mg/mL) was diluted with mobile phase to obtain working standard solutions in the concentration range of 1-120 μg/mL RXN. Each concentration was injected into the HPLC system thrice. The mean peak area versus corresponding concentrations of RXN was plotted and the calibration curve was drawn. The concentration of the RXN in unknown samples was read from the calibration curve or computed from the regression equation.
Analysis of RXN in tablets
Twenty tablets were weighed and subsequently powdered. An accurately weighed amount of powder equivalent to 50 mg RXN was transferred into a 50 mL volumetric flask and dissolved in 20 mL of mobile phase. This mixture was sonicated for 15 minutes and the resulting solution was then filtered through a 0.45 μm membrane filter, followed by the addition of mobile phase to the 50 mL mark to obtain a stock solution (1 mg/mL). The stock solution was appropriately diluted with mobile phase to obtain the suitable working concentration (80 μg/mL). The working standard solution was injected into the HPLC system thrice. The concentration of the RXN in the tablets was calculated using the calibration curve or from the regression equation.
Analysis of Placebo blank solution
An accurately weighed amount of starch (10 mg), acacia (10 mg), hydroxyl cellulose (10 mg), sodium citrate (10 mg), talc (10 mg), magnesium stearate (10 mg), lactose (10 mg), glucose (10 mg) and sodium alginate (10 mg) were transferred into a 50 mL volumetric flask containing 30 mL of mobile phase. This mixture was sonicated for 15 minutes, filtered and followed by the addition of mobile phase to the 50 mL mark. This solution was injected into the HPLC system.
Procedure for forced degradation studies
Acid and alkali degradation
In order to perform acid and alkaline degradation, 100 mg of RXN was mixed with 10 mL of 0.1 N HCl and 0.1 N NaOH in 100 mL volumetric flasks, respectively. The solutions were allowed to react for 2 hours at 80ºC temperature in the water bath. After that, the solutions were neutralized with 0.1 N HCl (alkaline degradation), 0.1 N NaOH (acid degradation) and then diluted with mobile phase up to the mark.
Oxidative degradation
To promote the oxidation, 100 mg of RXN was mixed with 10 mL of 3% H 2 O 2 in 100 mL volumetric flask and left to react for 2 hours at 80 ºC temperature in the water bath. After oxidation, the solution was diluted with mobile phase up to the mark.
Dry heat degradation
For this purpose, 100 mg of RXN was taken in glass petri dish and kept in a hot air oven (105 °C) for 2 hours. After the specified time, the sample was transferred to a 100 mL volumetric flask containing 30 mL of mobile phase, mixed well and diluted up to the mark with mobile phase.
Photolytic degradation
For photolytic degradation, 100 mg of RXN was taken in a glass petri dish and exposed to sunlight for 24 h. After the degradation, the sample was transferred to a 100 mL volumetric flask containing 30 mL of mobile phase and mixed well. The volume of the flask was completed up to mark with mobile phase.
The above degraded sample solutions were filtered and appropriately diluted with mobile phase to 80 μg/mL of RXN. The degraded sample solutions were injected into the HPLC system. The respective chromatograms and peak area were recorded.
Results and Discussion
Method development
During the method development two columns [thermo BDS hypersil-C8 (250 mm x 4.6 mm x 5 μm) and ACE-Ciano column (250 mm x 4.6 mm, 5 μm particle size)], different pH values (3) (4) (5) (6) (7) and two organic solvents (methanol and acetonitrile) were tested. Acceptable separation, peak shape and symmetry, with a retention time of 4.462 minutes, were achieved with ACE-Ciano column (250 mm x 4.6 mm, 5 μm particle size), mobile phase consisting of 0.1 M Sodium acetate (pH 5.5): methanol (60:40, v/v) at 1 mL/min flow rate and 30 o C temperature. The RXN solution in mobile phase was scanned by UV-visible spectrophotometer. It was observed that the maximum absorbance of RXN was obtained at 247 nm.
Method validation System suitability
For this purpose, five replicate injections of freshly prepared standard solutions (80 μg/mL) were made. Percentage relative standard deviation of the system suitability parameters was calculated. The low percentage relative standard deviation values (Table 1) indicate that all the system suitability parameters are within the acceptable limits. 
Sensitivity (LOD and LOQ)
For the determination of LOD and LOQ, five replicate injections of dilute solutions with known concentration (1 μg/mL) were injected into the HPLC system. The LOD and LOQ of the method are found to be 0.194 μg/mL and 0.648 μg/mL, respectively. These values indicate the excellent sensitivity of the proposed method.
Precision and Accuracy
The intra-and inter-day precision and accuracy of the method was carried out at three different concentration levels (1 μg/mL, 80 μg/mL and 120 μg/mL). The precision and accuracy was expressed in terms of percentage relative standard deviation (%RSD) and percentage recovery, respectively. The low %RSD (<1) and good percentage recovery values showed that the precision and accuracy of the method was good (Table 2) .
Recovery studies via standard addition method
The accuracy of the proposed method was further assessed by carrying out recovery studies through standard addition method. The preanalyzed tablet samples were spiked with 50%, 100% and 150% of RXN found in tablet sample. The percent recovery values (Table 3) indicate that the recovery was good and the excipients present in the tablet dosage form did not interfere in the assay of RXN. 
Selectivity
The selectivity of the method was evaluated through the comparison of the chromatograms of placebo blank solution, blank mobile phase and tablet sample solution with the standard drug solution (80 μg/mL). There is no peak interference of mobile phase blank, placebo blank and tablet excipients at the retention time of RXN (Figure 1) . The results established the selectivity of the method. 
Specificity
In order to evaluate the specificity of the proposed method, forced degradation studies were performed. The samples submitted to acid and alkaline conditions, RXN content had a decrease of 7.705% and 8.851%, respectively. When the oxidation with H 2 O 2 was promoted, the RXN content had a decrease of 6.559%. When the RXN powder was exposed to dry heat at 105°C for 2 hours, 9.186% of RXN degradation was observed. 7.304% of RXN degradation was observed after exposure of solid drug to sunlight for 24 hours. The chromatograms recorded for the degradation samples revealed no peaks within retention time of RXN (Figure 2 ). The good resolution of RXN peak and the degradation product in all the situations could be observed, indicating the specificity of the method. 
Robustness
The robustness of the method was determined by analyzing the RXN under a variety of conditions of the method parameters, such as the mobile phase ratio, pH of the mobile phase, flow rate and column temperature. The low %RSD values (<1) ( 
Application to tablet dosage forms
The tablet formulations containing RXN were analyzed using the developed HPLC method. The percent recovery was 99.74%, while the RSD value was 0.421%. The recovery value indicates the non interference of commonly added tablet excipients with the assay.
Comparison of the proposed method with the reported methods
In comparison with the earlier reported methods for the quantification of RXN (Table 5) , the proposed method has the advantages such as broad linearity range [6] [7] [8] [9] 16 , more precise 3-6,13,14 , more accurate [3] [4] [5] [6] 8, 11, 13, 14 and sensitive [5] [6] [7] . Unlike the bioanalytical methods [8] [9] [10] [11] [12] , the proposed method does not require cumbersome extraction procedure, internal standard, costly detector system and expertise operational personnel. The reported RP-HPLC and stability indicating HPLC methods used acetonitrile in their mobile phase which probably will raise the cost of the method. In all the reported methods, except the HPLC method reported by Çelebier et al. 13 forced degradation studies were not reported. Some of the methods 4, [8] [9] [10] [11] [12] 14 were not applied to tablet formulations. 
Conclusion
A new stability indicating HPLC method was developed and validated for the determination of rivaroxiban. The ICH guideline was adhered for method validation. Satisfactory sensitivity, precision, accuracy, selectivity, specificity and minimum cost are the main features of the developed method. The present study demonstrates the degradation vulnerability of rivaroxiban to different stress conditions. The method was proved adequate for quantitative determination of rivaroxiban in presence of its degradation products. The method was found to be suitable for the analysis of rivaroxiban in tablet dosage form.
